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Objective: Graves’ disease is the commonest cause of hyperthyroidism in populations
with sufficient dietary iodine intake. Anti-thyroid drugs (ATD) are often used as the initial
treatment for Graves’ hyperthyroidism, however there is a paucity of data relating the
dose of ATD therapy to the effect on thyroid hormone levels, increasing the risk of both
over- and under-treatment. We aimed to determine the pharmacodynamic response to
the ATD carbimazole.
Design: Retrospective cohort study.
Methods: Participants were patients (n = 441) diagnosed with Graves’ disease at
Imperial College Healthcare NHS Trust between 2009 and 2018. The main outcome
measure was change in thyroid hormone levels in response to ATD.
Results: Baseline thyroid hormone levels were positively associated with TSH receptor
antibody titres (P < 0.0001). Baseline free triiodothyronine (fT3) were linearly related
to free thyroxine (fT4) levels in the hyperthyroid state (fT3 = fT4∗0.97–11), and fell
proportionately with carbimazole. The percentage falls in fT4 and fT3 per day were
associated with carbimazole dose (P < 0.0001). The magnitude of fall in thyroid
hormones after the same dose of carbimazole was lower during follow up than at the
initiation visit. The fall in thyroid hormone levels approximated to a linear response if
assessed at least 3 weeks after commencement of carbimazole. Following withdrawal
of antithyroid drug treatment, the risk of relapse was greater in patients with higher initial
fT4, initial TSH receptor antibody titre, males, smokers, and British Caucasian ethnicity.
Conclusion: We identify a dose-response relationship for fall in thyroid hormones in
response to carbimazole to aid in the selection of dose for Graves’ hyperthyroidism.
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INTRODUCTION
Overt hyperthyroidism affects 1.3% of people in iodine-replete
populations (1) and if untreated is associated with a catabolic
state characterized by weight loss, reduced bone mineral density,
atrial fibrillation, and thromboembolic events (2, 3). Graves’
disease is the commonest cause of hyperthyroidism accounting
for up to 80% of cases (4–6), with a lifetime prevalence of 3% in
women and 0.5% in men (1, 7).
Recent evidence suggests that rapid control of
hyperthyroidism in Graves’ disease, whilst avoiding over-
treatment, is desirable. A low thyroid stimulating hormone
(TSH) level at 1 year following diagnosis of Graves’ disease
was associated with a 55% increase in cardiovascular mortality
independent of treatment modality (8). Similarly, every 6
months’ duration with suppressed TSH levels in patients with
hyperthyroidism was associated with a 11–13% increase in total
mortality (9). Conversely, even transient hypothyroidism during
treatment has been associated with greater weight-gain than
those without over-treatment following anti-thyroid medications
(10). Moreover, avoidance of hypothyroidism is recommended
to prevent exacerbation of thyroid eye disease (11). Thus,
the prompt and sustained normalization of thyroid hormone
levels is of foremost importance in the management of patients
diagnosed with Graves’ disease (7).
Treatment modalities for the management of Graves’
hyperthyroidism include anti-thyroid drugs (ATD), radioactive
iodine (RAI) therapy, or total thyroidectomy. ATD is favored
as first line therapy in Europe, with remission achieved in
approximately half of patients after a 12–18 month duration
of treatment (6, 12, 13). Traditionally, radioactive iodine has
been preferred in USA (7), although recent American Thyroid
Association (ATA) guidelines have suggested that ATD can also
be considered as first line (14). However, a pharmacodynamic
relationship between ATD and thyroid hormone levels has yet to
be clearly described.
Thionamides inhibit the thyroid peroxidase enzyme to reduce
thyroid hormone synthesis (15). In the UK, the two predominant
ATDs used are carbimazole (which is entirely metabolized to
methimazole), and propylthiouracil (PTU). Methimazole has a
longer half-life (t1/2 4–6 h) than PTU (t1/2 75min), enabling
once-daily administration, whereas PTU is given as multiple
doses over a day (15, 16). Blood levels of both drugs peak
1–2 h following ingestion, with inhibition of thyroid hormone
synthesis lasting for 12–24 h following PTU (17) and >24 h
following methimazole (15, 18). ATDs may be given either
via a “dose titration” regimen whereby initial higher doses are
reduced over time, or as a “block and replace” regimen using
fully inhibitory doses of ATDs with concomitant thyroxine
replacement to maintain euthyroidism. Neither approach has
been reliably demonstrated as superior in achieving remission
(19). However, the dose-titration regimen is associated with
lower doses of ATDs, and thus a potentially reduced risk of
dose-related side-effects such as agranulocytosis (20). Likewise,
rates of discontinuation due to side-effects from ATDs are lower
following the “dose-titration” method compared to “block and
replace” (19–22).
To date, there is a paucity of evidence to describe the
pharmacodynamic response between the dose of ATD and the
resultant reduction of thyroid hormone levels. Consequently,
many clinicians adopt experience-based strategies to prescribe
ATDs. For example, Abraham and colleagues recommend
initiating carbimazole/methimazole with a dose of 10–20mg
once daily if fT4 is <40 pmol/l and 40mg once daily if fT4 is
>40 pmol/l and then halving the dose following 1 month of
treatment (23).
In summary, Graves’ disease is one of the most common
endocrine pathologies encountered by the endocrinologist, and
whilst medical therapy with ATD is often adopted as the first line
treatment modality, there is scarce data to support physicians in
selecting the dose of carbimazole for initiation and subsequent
dose-titration. In the present study, we aimed to determine the
pharmacodynamic relationship between dose of carbimazole and
resultant change in thyroid hormone levels. We also investigated
baseline factors that could predict the chance of spontaneous
remission following ATDs in aUKpopulation to inform the likely
success of medical therapy.
MATERIALS AND METHODS
Study Design
We undertook a retrospective analysis of patients attending
Imperial College Healthcare NHS Trust between 2009 and 2018,
who had been diagnosed with Graves’ disease and treated with
anti-thyroid drugs. This audit was registered with Imperial
College NHS Healthcare Trust (registration number ASM_024).
Study Participants
Participants had a diagnosis of hyperthyroidism due to Graves’
disease confirmed by: biochemical hyperthyroidism and positive
thyroid stimulating hormone (TSH) receptor autoantibody (>0.3
U/mL) or a technetium thyroid scan consistent with Graves’
disease. Biochemical hyperthyroidism was defined as a supressed
TSH (<0.3 mU/L), elevated free thyroxine (fT4) (>23.0 pmol/L),
and/or elevated free triiodothyronine (fT3) (>5.7 pmol/L).
Exclusion criteria included patients with thyrotoxicosis but
unconfirmed Graves’ disease, and those with dual thyroid
pathology, and patients who were pregnant at the time of
diagnosis. Demographic data, initial thyroid hormone levels,
thyroid antibody titres, doses of ATDs, follow-up thyroid
hormone levels, and clinical course were reviewed.
Standard Care at Our Centre
Patients included in this study were treated with a dose-titration
regimen. The highest initial dose for commencing treatment was
40mg daily for patients with elevated thyroid hormone levels.
A lower dose without clear parameters was used for patients
with lower levels of thyroid hormones based on individual
endocrinology physician’s practice. Patients are usually reviewed
every 4–6 weeks during the first few months of treatment until
thyroid hormone levels have stabilized. Treatment is continued
for at least 18 months before withdrawal of ATD medication
is trialed. Patients have measurement of their thyroid hormone
levels 4 weeks after cessation of ATDs. Those that have normal
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thyroid function tests at this juncture are discharged with a
recommendation for infrequent monitoring in primary care (e.g.
6 monthly, or sooner if symptoms recur). If thyroid function
testing suggests persistence/relapse of thyrotoxicosis, antithyroid
drug therapy is restarted, and the patient is recommended to
have definitive management with radioiodine therapy or surgery.
Both those with persistence of disease on withdrawal and those
with initial remission but subsequent relapse were included in
the assessment of patients with relapse, with at least 3 months’
follow-up following drug cessation. The weightings for individual
aspects of the relapse rate score were assigned according to the
frequency of relapse in the indicated subgroups.
Hormonal Assay Methodology
Serum TSH, fT4 and fT3 levels were measured using automated
chemiluminescent immunoassays (Abbot Diagnostics,
Maidenhead, UK). Interassay coefficients of variation were:
TSH ≤5.3%, fT4 ≤6.3%, and fT3 ≤5%. Limits of detection for
each assay were as follows: TSH ≤0.0025 mU/l, fT4 5.15 pmol/l,
fT3 1.536 pmol/l. TSH receptor antibody titre was measured
using third generation ELISA kit (RSR laboratories, Cardiff,
United Kingdom) with interassay coefficient of variation of
8.8% and lower limit of detectability of 0.08 u/L. TPO antibody
titre was measured using ELISA (Orgentecs) with interassay
coefficient of variation of 8.5% and a measuring range of
0–3,000 U/ml.
Statistical Analysis
Data was analyzed using GraphPad PRISM version 7.0 and
STATA version 14.0. Data distribution was assessed using
D’Agostino and Pearson normality test. Parametric data was
presented as mean ± standard deviation (SD), whereas non-
parametric data was presented as median with interquartile range
(IQR). Non-parametrically distributed data were compared using
Kruskal-Wallis test with post-hoc Dunn’s, or Mann-Whitney U-
tests. Data with multiple groups parametrically distributed was
compared by one-way analysis of variance (ANOVA). Categorical
data were compared using logistic regression. Simple linear
regression was used to determine the association between two
variables. Multivariable linear regression was used to assess the
association of TSH receptor antibody titre, TPO antibody titre,
smoking status, ethnicity, and gender with serum fT4 levels.
Multivariable logistic regression was used to assess the effect on
remission of the following baseline variables: gender, smoking,
ethnicity, TPO antibody status, TSH receptor antibody titre,
initial fT4 level, and final fT4 level. A P < 0.05 was regarded as
statistically significant.
The daily dose-response relationship for fall in thyroid
hormones in response to carbimazole was derived from linear
regression models for the percentage fall in fT4 and fT3 levels
between visits. The formula used is fT4(n+1) = fT4(n) –
(m∗Dose∗fT4(day n)+ c), where fT4(n) is the level on day n after
initial visit; Dose is the carbimazole taken each day between visits;
m is the slope of the linear model determined from the data; c is
the intercept of the same model. The formula for fT3 is the same.
Slope and intercept values were adjusted for weight at initial visit.
Since, for constant dose, the fall in fT4 and fT3 levels between first
TABLE 1 | Baseline characteristics of patients with Graves’ disease.
N
Total number of patients reviewed 526
Total number of patients with complete records 441
Follow up duration (days) 328 (158–544)
Age (years) 44 (± 15)
Sex
Male (%) 82 (18.6%)
Female (%) 358 (81.4%)
Ethnicity
Black (African and Caribbean) (%) 50 (11.4%)
White (Caucasian) (%) 159 (36.1%)
Asian (%) 47 (11.0%)
Mixed (%) 10 (2.3%)
Other (%) 87 (20.0%)
Unknown (%) 87 (20.0%)
Continuous variables displaying parametric distribution are presented as mean ±
standard deviation (SD), whereas non-parametric variables are presented as median with
interquartile range (IQR).
and second visit is bigger than the fall between second and third
visits and between third and fourth visits, we refined the initial
model to incorporate (a) slope and intercept values derived from
regression analysis for the time between each visit and (b) a dose
exponent factor that accounts for the increased fall. Hence the
overall model for is fT4(n+1) = fT4(n) – (m∗Dosep∗fT4(day n)
+ c), with p representing the dose exponent and all other variable
definitions unchanged. Absolute measure of model fit is reported
as root mean square error (RMSE) in pmol/L, the square root of
the variance of the residuals, with zero indicating a perfect fit.
RESULTS
Baseline Characteristics
We reviewed medical records of 526 patients with thyrotoxicosis
and identified 441 patients with a confirmed diagnosis of Graves’
disease. Mean (±SD) age was 44 (±15) years and 81% of
patients were female (Table 1). Patients were followed up for a
median duration of 328 days (range 7–1,443 days). TSH receptor
antibody titres were recorded for 99.1% (n= 437) of patients with
a median titre of 4.1 U/ml (IQR 1.95–8.0 U/ml). TPO antibodies
were measured in 59.0% (n = 260) of patients (median 139, IQR
0–385 U/ml).
Baseline Thyroid Hormone Levels
FT4 levels and fT3 levels were associated with TSH receptor
antibody titre (r2 = 0.11 and r2 = 0.12, respectively, P < 0.0001).
Initial fT4 (Figure 1A) and fT3 levels (Figure 1B) were higher in
patients with greater TSH receptor antibody titres at diagnosis (P
< 0.0001). The ratio of fT4:fT3 before treatment was ∼2:1, and
fT3 could be predicted from fT4 levels using the equation fT3
= 0.97∗fT4-11, (r2 = 0.68, P < 0.0001) (Figure 1C). Age, sex,
ethnicity, and smoking status were not associated with initial fT4
levels by linear regression.
Frontiers in Endocrinology | www.frontiersin.org 3 May 2020 | Volume 11 | Article 286
Abbara et al. Endocrine Response to Anti-thyroid Drugs
FIGURE 1 | (A) Bar graph (median with IQR) of initial fT4 (pmol/l) by initial TSHR antibody titre (mU/l). Initial fT4 (pmol/l) increased with TSHR antibody titre (*P < 0.05,
**P < 0.01, ****P < 0.0001). Initial fT4 levels were predicted by initial TSHR antibody titre (r2 = 0.11, P < 0.0001). (B) Bar graph (median with IQR) of initial fT3 (pmol/l)
by initial TSHR antibody titre (mU/l). Initial fT3 (pmol/l) increased with TSHR antibody titre (*P < 0.05, ***P < 0.001, ****P < 0.0001). Initial fT3 levels were predicted by
initial TSHR antibody titre (r2 = 0.12, P < 0.0001). (C) Scattergraph of initial fT4 (pmol/l) by initial fT3 (pmol/l). Initial fT4 and fT3 increased in an ∼1:1 ratio, with fT4
predicting fT3 levels (fT3 = (0.97 × fT4)-11, r2 = 0.68, P < 0.0001). (D) Scattergraph of fall in fT3 (pmol/l) per day by fall in fT4 (pmol/l) per day, following 4 weeks’ of
treatment with carbimazole. Fall in fT4 per day (pmol/l) predicted fall in fT3 per day (pmol/l) by the equation: Fall in fT3 per day = 0.9541* Fall in fT4/day + 0.02, r2 =
0.58, P < 0.0001.
Change in Thyroid Hormone Levels in
Response to Carbimazole
Following initiation of antithyroid treatment with carbimazole,
both fT3 and fT4 decreased proportionately in a 1:1 ratio (r2
= 0.58, P < 0.0001) (Figure 1D). As a first pass analysis, we
plotted the absolute fall in fT4 per day by dose of carbimazole for
all visits (Figure 2A). We then selected only patients receiving
20mg of carbimazole to demonstrate that the absolute fall in
fT4 per day was proportional to the baseline fT4 level prior
to commencing that dose (Figure 2B). Thus, we used fall in
fT4 from baseline expressed as a percentage for subsequent
analyses (Figure 2C). We examined the interval required for
reliable assessment of percentage change in fT4 following
each dose of carbimazole. We observed that the relationship
between the fall in fT4 and time is curvilinear with a rapid
fall during the first 21 days following initiation of 20mg of
carbimazole (Figure 2D). However, the percentage fall in fT4
per day approximates to a linear relationship after 21 days and
thus for subsequent analyses of dose response with carbimazole
we excluded data with intervals shorter than 21 days. The
relationship between fall in fT4 and dose of carbimazole was
altered by duration from first commencement of carbimazole.
Indeed, the percentage fall in fT4 per day after the same dose
of carbimazole (20mg) was reduced in patients with a longer
duration since initial presentation (r = −0.015, r2 = 0.29,
P < 0.0001).
Pharmacodynamic Response to Dose of
Carbimazole
The percentage fall in fT4 per day was associated with
carbimazole dose both at initial (Figure 3A) and follow-up
assessments (Figure 3B). Notably, the median percentage
reduction in fT4 levels was lower at follow-up assessment
compared to initial assessment (Figure 3C). A similar dose-
response relationship was observed for fT3 levels (Figures 3D–F)
and for absolute reductions in thyroid hormone levels
(Supplemental Figure 1). Neither gender (P = 0.61), nor
smoking status (P = 0.17), influenced thyroid hormonal
response to carbimazole. Similarly, neither body-weight (P =
0.35), nor splitting the dose of carbimazole during the day (P =
0.36) influenced the fall in fT4 levels following carbimazole.
The daily dose-response relationship for fall in thyroid
hormones in response to carbimazole formula is fT4(n+1) =
fT4(n) – (m∗Dose∗fT4(day n) + c), where fT4(n) is the level on
day n after initial visit; Dose is the carbimazole dose taken each
day between visits; m is the slope of the linear model determined
from the data; c is the intercept of the same model. Although
body-weight was not a significant factor in regression modeling
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FIGURE 2 | (A) Bar graph of absolute fall in fT4 per day by carbimazole dose across all study visits (**P < 0.01, ***P < 0.001, ****P < 0.0001). (B) Scattergraph of
absolute fall in fT4 per day (pmol/L) in patients receiving 20mg carbimazole daily following initial visit (absolute fall in fT4 per day = 0.018*initial fT4 −0.27, r2 = 0.40, P
< 0.0001). (C) Scattergraph of percentage fall in fT4 per day (%) between the first and second visits in patients receiving 20mg carbimazole daily following their initial
assessment (% fall in fT4 per day = −0.015 * number of days between visits + 1.693, r2 = 0.30, P < 0.0001). (D) Scattergraph of percentage fall in fT4 per day (%) in
patients taking 20mg carbimazole by time elapsed (days) between the first and second visits.
over several weeks, adjustment of the slope, and intercept values
depending on body-weight at first visit slightly increases the
conformity of the dose-response model to observations (root
mean square error RMSE when comparing observations to
predictions falling from 4.44 to 4.28 pmol/L for fT4 and from 3.01
to 2.67 pmol/L for fT3). The derived slope and intercept values
are given in Supplemental Table 1. The power model derived to
account for greater fall in fT4 and fT3 levels for a given dose after
the first and second visit has similar RMSE. Themodels have been
implemented as a web application, available at https://wkapps.
host.cs.st-andrews.ac.uk/Graves.
Time to Achieve Euthyroid Status and Risk
of Overtreatment
In patients with at least 2 months’ duration of treatment (n =
422), the majority (95%) achieved normal fT4 and fT3 levels (95
and 74%, respectively). Euthyroid status, defined as having TSH,
fT4, and fT3 all within range, was achieved by 28% of patients at
a median time of 192 days (range 84–407 days). Similarly, 29% (n
= 98) of patients were over-treated and rendered hypothyroid as
indicated by either a TSH >4.2 mU/l, or fT4 <9 pmol/l. Greater
initial carbimazole dose (P = 0.04) and higher initial fT4 level
(P = 0.04) increased the risk of over-treatment when assessed by
univariate logistic regression, whereas initial TPO antibody titre
(P= 0.09), TSH receptor antibody titre (P= 0.79), sex (P= 0.23),
ethnicity (P = 0.40), age (P = 0.86), and smoking status (P =
0.36) were not significant predictors.
Risk Factors for Relapse
Of the study cohort, 120 patients had completed 18 months’
of antithyroid treatment and had a trial off treatment with
carbimazole. Of these, 19% (n = 23) had evidence of
relapse/persistent disease at the first clinical assessment following
cessation of antithyroid medication, and a further 16% (n =
19) had relapse at subsequent assessments with median time to
relapse being 85 days (range 25–335 days). Thus, 35% (n= 42) in
total had relapse following cessation of medical therapy.
An increased frequency of relapse was observed in males
(Figure 4A), white British ethnic origin (Figure 4B), and current
or previous smoking (Figure 4C) (Table 2). Those with an initial
fT4 >45 pmol/l had an increased odds of relapse compared
to those with a fT4 <28 pmol/l (OR 7.5, 95% CI 1.69–33.27)
(Figure 4D). Patients with a greater TSH receptor antibody titre
at diagnosis also had an increased odds of relapse (OR 3.69
if TSHrAb >9 vs. <3 mU/L, 95% CI 1.32–10.29) (Figure 4E)
(Table 2). Similarly, patients with a higher fT4 at the final visit
prior to withdrawal of carbimazole had an increased odds of
relapse (Figure 4F; OR 3.41 if fT4 >15 pmol/l vs. <12 pmol/l,
95% CI 1.07–10.87) (Table 2). In an adjusted multivariable
logistic regression model (r2 = 0.09, P = 0.04) including
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FIGURE 3 | (A) Bar graph of percentage fall in fT4 per day in patients on carbimazole following their initial visit with groups compared using Kruskal-Wallis test with
post-hoc Dunn’s test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (B) Bar graph of percentage fall in fT4 per day in patients on carbimazole following their
follow-up visit with groups compared using Kruskal-Wallis test with post-hoc Dunn’s test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (C) Scattergraph of
median percentage fall in fT4 per day in patients receiving carbimazole at both initial and follow-up visits.
Initial median % fall in fT4 per day = 0.04* carbimazole dose + 0.09, r2 = 0.93, P = 0.0004. Follow-up median% fall in fT4 per day = 0.03*carbimazole dose −0.17,
r2 = 0.97, P = 0.0005. (D) Bar graph of percentage fall in fT3 per day in patients on carbimazole following their initial visit with groups compared using Kruskal-Wallis
test with post-hoc Dunn’s test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.000). (E) Bar graph of percentage fall in fT3 per day in patients on carbimazole following
their follow-up visit with groups compared using Kruskal-Wallis test with post-hoc Dunn’s test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). (F) Scattergraph
of median percentage fall in fT3 per day in patients receiving carbimazole at both initial and follow-up visits.
Initial median% fall in fT3 per day = 0.05* carbimazole dose + 0.16, r2 = 0.91, P = 0.0008. Follow-up median% fall in fT3 per day = 0.03* carbimazole dose −0.23,
r2 = 0.98, P = 0.0002.
ethnicity, gender, age, smoking status, TSHR and TPO antibody
titre, and initial fT4 measurement, only initial fT4 significantly
predicted risk of relapse (P = 0.02).
We generated a “relapse risk score” (RRS) based on the risk
of relapse with each of the following baseline variables: initial
fT4, TSHR ab, gender, smoking status, and ethnicity (Figure 5).
The different weightings for individual aspects of the relapse rate
score were assigned according to the frequency of relapse in the
indicated subgroups. The risk of relapse in those with an RRS
>20 was increased by 36-fold compared to those with an RRS
of <15 (OR 36.0, 95% CI 3.2–405.9, P = 0.004) (Figure 5).
DISCUSSION
Graves’ disease is the commonest cause of hyperthyroidism
(24), and prompt achievement of euthyroidism is a fundamental
therapeutic goal (14). In the present study, we report a
pharmacodynamic relationship between the dose of carbimazole
and the fall in thyroid hormone levels, to aid clinicians in the
rapid achievement of euthyroidism whilst avoiding the sequelae
of overtreatment and hypothyroidism.
In our cohort, we observed a female preponderance (female:
male ratio of ∼4:1), consistent with studies undertaken in the
UK (25), and other iodine replete areas (1) including Sweden
(26), Denmark and Iceland (27). The mean age of 44 years of our
cohort is consistent with the reported peak incidence of Graves’
disease in the third to fifth decades (1, 27, 28). Patients with
higher TSHR antibody titres had higher initial fT4 and fT3 levels.
TSHR antibody titre is considered a marker of severity of Graves’
disease, with higher titres at diagnosis being associated with a
longer time to achieve euthyroid status (29).
Initial fT4:fT3 ratio was ∼2:1 ratio; a measure which
has been reported to provide diagnostic value to distinguish
hyperthyroidism due to Graves’ disease from other etiologies
(30–32). Izumi and colleagues reported a similar fT4:fT3 ratio
in patients with Graves’ thyrotoxicosis (2.5:1), whereas patients
with painless thyroiditis had a ratio of 3.3:1 (31). Serum fT3 and
fT4 levels were increased and fell proportionately in response to
treatment in a∼1:1 ratio. This is in contrast to the higher ratio of
fT4:fT3 observed in the euthyroid state and reflects upregulation
of the type 2 deiodinase enzyme with thyrotoxicosis. This data
supports the use of fT4 alone in the monitoring of response to
medical therapy.
This observation also explicates the phenomenon of “T3
toxicosis”—a condition occurring in <5% of all patients with
hyperthyroidism, where only fT3, but not fT4, is raised above
the reference range (33). As hyperthyroidism is associated with
thyroidal up-regulation of type 2 deiodinase, there is an increased
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FIGURE 4 | (A) Bar graph showing relapse rates in patients receiving at least 18 months’ of treatment (n = 120) by sex. Male patients were nearly 1.5 times more
likely to experience relapse compared with female patients. (B) Bar graph showing relapse rates in patients receiving at least 18 months’ of treatment (n = 120) by
ethnicity. Relapse was most likely in patients of white British origin, having an almost 4-fold increased risk of relapse compared with Asian patients. (C) Bar graph
showing relapse rates in patients receiving at least 18 months’ of treatment (n = 120) by smoking status. Risk of relapse was over 50% more likely in patients who had
ever smoked, compared to those who had never smoked. (D) Bar graph showing relapse rates in patients receiving at least 18 months’ of treatment (n = 120) by
initial fT4. Patients with an initial fT4 >45 pmol/l were a third more likely to experience relapse, than those with an initial serum fT4 <23 pmol/l. (E) Bar graph showing
relapse rates in patients receiving at least 18 months’ of treatment (n = 120) by initial TSH receptor antibody titre. There was a trend to increasing risk of relapse as
initial TSH receptor antibody titre increases with those with a titre >9 mU/l having a >2-fold increase in risk of relapse, compared to those with an initial TSH receptor
antibody titre <2 mU/l. (F) Bar graph showing relapse rates in patients receiving at least 18 months’ of treatment (n = 120) by serum fT4 (pmol/l) at the final visit. As
serum fT4 increased, so did the risk of relapse, with patients with a serum fT4 in the upper range of normal (>15 pmol/l) having a relapse rate more than twice that of
those with a final serum fT4 in the lower part of the reference range (<12 pmol/l).
conversion of T4 to T3 resulting in a reduced fT4:fT3 ratio than
in the euthyroid state (34). As the euthyroid reference range for
fT3 is lower than that for fT4, this results in fT3 being more
frequently outside the euthyroid reference range than fT4. Thus,
this suggests that “T3 toxicosis” is a function of the euthyroid
reference ranges and represents a mild form of Graves’ disease,
rather than being a distinct disease entity.
Carbimazole has a plasma half-life of ∼5.3 h (35), and
traditionally was prescribed in divided doses (36). However,
several studies have demonstrated that a single dose of
carbimazole is just as effective at inducing euthyroidism (16,
37–40). Furthermore, methimazole is concentrated in thyroid
follicular tissue (41, 42) and has a longer biological duration
of action than suggested by pharmacokinetic levels. Moreover,
compliance is increased by once daily dosing of ATD (43). In the
present study, we did not find any evidence that splitting the dose
or adjusting the dose for body weight significantly altered the fall
in the thyroid hormones following carbimazole.
We observed that the absolute fall in fT4 per day was
directly proportional to the initial fT4 level, and thus we used
a percentage fall in fT4 to investigate a pharmacodynamic
relationship. Notably, a lesser reduction in percentage fall in fT4
was observed with increased duration from initial diagnosis. We
identified that an interval of at least 21 days was required to
reliably assess repeat fT4 levels. We had insufficient numbers
of patients receiving PTU to conduct a precise dose-response
relationship (n = 10–11 per timepoint), however patients on
200–400mg of PTU had 1% reduction in fT4 per day, as
observed with 30mg of carbimazole, consistent with the 10-
fold dosing equivalence to carbimazole reported in the literature
(14, 44). Our dose-response models have acceptable fit to the
data, with typical model error within 4.28 pmol/L for fT4 being
12.8% of the mean initial level of 33.4 pmol/L, and with typical
model error within 2.67 pmol/L for fT3 being 13.8% of the
mean initial level of 19.3 pmol/L. The models therefore provide
useful indicative comparisons of the effects of different doses for
patients with known baseline fT4 and fT3 levels. In this sense
the models form an intermediate stage in the development of
fully clinically valid dose-response models. The further work
needed to derive clinically valid models is (a) the incorporation
of more longitudinal data, (b) careful mixed effects analysis
to determine posterior predictive p-values, and (c) external
validation by assessing predictions for observations not used to
derive the models.
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TABLE 2 | Risk factors for relapse.
Risk Factor % of patients with relapse Odds ratio 95% CI P-value Adjusted odds ratio 95% CI P-value
Sex 0.11 0.11
Male 52%
Female 33% 0.44 0.16–1.20 0.38 0.12–1.23
Ethnicity 0.18
Asian 21%
Black 28% 1.41 0.27–7.27 0.68 7.05 0.91–54.64 0.06
Other 35% 2.00 0.49–8.10 0.33 1.40 0.23–8.67 0.72
White 52% 3.92 0.90–17.08 0.07 3.67 0.68–19.92 0.13
Smoking status 0.41
Non-smoker 32%
Ex smoker 44% 1.70 0.59–4.89 0.32 2.30 0.60–8.79 0.22
Current smoker 47% 1.86 0.60–5.76 0.28 0.54 0.10–2.88 0.47
TSHR titre (u/mL) 0.09
<3 27%
3–5.9 31% 1.24 0.48–3.26 0.66 0.96 0.25–3.61 0.95
6–9.0 38% 1.66 0.61–4.49 0.32 3.16 0.78–12.81 0.11
>9 57% 3.69 1.32–10.29 0.01 7.95 1.96–32.24 0.004
Free T4 (pmol/L) at initial visit 0.02
<28 17%
28–44.9 39% 3.2 0.92–11.1 0.07 1.38 0.47–4.04 0.55
>45 60% 7.5 1.69–33.27 0.0008 2.39 0.29–19.84 0.42
Free T4 (pmol/L) at final visit 0.12
<12 21%
12–15 34% 2.81 0.58–13.7 0.20 3.00 0.65–13.83 0.16
>15 50% 3.41 1.07–10.87 0.05 5.67 0.85–37.62 0.07
Rates (%) of relapse are presented for risk factors investigated. Rates of relapse were compared using logistic regression, with both adjusted and unadjusted odds ratios presented.
FIGURE 5 | According to their relationship to risk of relapse, values were assigned to parameters to devise the “Relapse Rate Score”. Observed relapse increased with
relapse rate score, such that those with a score >20 had an 80% chance of relapse, compared to 10% chance of relapse in patients with a relapse rate score of <15.
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Reported relapse rates following treatment with antithyroid
treatment are higher compared with radioactive iodine (RAI)
or surgery (45). It therefore could be advantageous to identify
patients with a greater chance of relapse based on baseline
characteristics to enable the stratification of patients who could
best be served by definitive management with radioiodine
or surgery at an earlier juncture. In our cohort, 35% of
patients who completed 18 months of treatment with antithyroid
therapy experienced subsequent relapse. The risk was increased
in men, white British ethnicity, smokers, and those with
higher fT4 and TSHR ab titres. Some reports have suggested
that smoking could modulate the immune response to make
relapse more likely (46, 47), although the exact mechanism
remains elusive. Similarly, patients with a final serum fT4
in the upper range of normal (≥15 pmol/l) were more
likely to experience relapse. An adjusted multivariable logistic
regression found that only initial fT4 predicted the odds
of relapse.
In a prospective, observational, multi-centre study, similar
rates of relapse to our study were reported, with 37% of
178 patients experiencing recurrent Graves’ hyperthyroidism
within 2 years after withdrawal of ATD. Younger age <40
yrs, higher serum fT4 level >40 pmol/l, higher serum TBII
titre, larger goiter size at diagnosis, and genetic factors
including PTPN22 C/T polymorphisms, and HLA subtypes
DQB1∗02, DQA1∗05, and DRB1∗03 were independent
risk predictors for recurrence (48). Based on these clinical
markers, the GREAT (Graves Recurrence Events After
Therapy) score was able to differentiate the risk of relapse
into three groups, whereby 68% of patients in the highest
risk group relapsed (vs. 16% in the lowest risk group) and
all did so rapidly within 6 months (48). Our proposed
relapse rate score appears to perform similarly well and
incorporates comparable variables, however external
validation, as discussed above, is required to validate this
proposed score.
There is a paucity of data describing the relationship
between carbimazole dose and the subsequent change in thyroid
hormone levels. Thus, these data represent an important
first step in establishing the relationship between dose and
pharmacodynamic response to carbimazole. However, it is
necessary to stress that as the models were developed using
retrospective data, external validation of the predictions outlined
in the present study is required prior to consideration for
clinical use.
In summary, we have identified a pharmacodynamic
relationship for medical therapy of Graves’ disease with dose of
carbimazole. The titration approach is desirable as it facilitates
reduced cumulative exposure to ATDs and thus carries a
lower risk of dose-related side effects. Whilst Graves’ disease
is one of the most common endocrine diseases treated, the
pharmacodynamic response to carbimazole has been poorly
defined, causing a residual significant risk of under- or over-
treatment. Thus, the relationships described in the present
study could aid in dose-selection and represents a useful initial
step to the estimation of factors that influence the response to
ATD therapy.
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Supplemental Figure 1 | (A) Bar graph of absolute fall in fT4 per day in patients
on carbimazole following their initial visit with groups compared using
Kruskal-Wallis test with post-hoc Dunn’s test (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P <
0.001, ∗∗∗∗P < 0.0001). (B) Bar graph of absolute fall in fT4 per day in patients on
carbimazole following their follow-up visit with groups compared using
Kruskal-Wallis test with post-hoc Dunn’s test (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P <
0.001, ∗∗∗∗P < 0.0001). (C) Scattergraph of median absolute fall in fT4 per day in
patients receiving carbimazole at both initial and follow-up visits. Initial median
absolute fall in fT4 per day = 0.01∗ carbimazole dose −0.01, r2 = 0.97,
P=<0.0001. Follow-up median absolute fall in fT4 per day = 0.007∗ carbimazole
dose −0.05, r2 = 0.99, P ≤ 0.0001. (D) Bar graph of absolute fall in fT3 per day in
patients on carbimazole following their initial visit with groups compared using
Kruskal-Wallis test with post-hoc Dunn’s test (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P <
0.001, ∗∗∗∗P < 0.000). (E) Bar graph of absolute fall in fT3 per day in patients on
carbimazole following their follow-up visit with groups compared using
Kruskal-Wallis test with post-hoc Dunn’s test (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P <
0.001, ∗∗∗∗P < 0.0001). (F) Scattergraph of median absolute fall in fT3 per day in
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patients receiving carbimazole at both initial and follow-up visits. Initial median
absolute fall in fT3 per day = 0.01∗carbimazole dose −0.02, r2 = 0.87, P =
0.0015. Follow-up median absolute fall in fT3 per day = 0.003∗carbimazole dose
– 0.03, r2 = 0.94, P = 0.0015.
Supplemental Table 1 | Dose-response coefficients. Weight dependent values of
percentage slope and intercept for use in the models for fT4 and fT3 fall given a
known dose. Entries are divided by 100 before use in the respective formula to
obtain absolute rather than percentage falls.
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